These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Sudden death related to toxicity in a patient on capecitabine and irinotecan plus bevacizumab intake: pharmacogenetic implications. Dahan L; Ciccolini J; Evrard A; Mbatchi L; Tibbitts J; Ries P; Norguet E; Mercier C; Iliadis A; Ouafik L; Lacarelle B; Seitz JF J Clin Oncol; 2012 Feb; 30(4):e41-4. PubMed ID: 22184401 [No Abstract] [Full Text] [Related]
11. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. Lou E; Turner S; Sumrall A; Reardon DA; Desjardins A; Peters KB; Sampson JH; Friedman HS; Vredenburgh JJ J Clin Oncol; 2011 Oct; 29(28):e739-42. PubMed ID: 21900098 [No Abstract] [Full Text] [Related]
12. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme. Zhang G; Huang S; Wang Z J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061 [TBL] [Abstract][Full Text] [Related]
13. Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Chamberlain MC Neurology; 2010 Jan; 74(2):181. PubMed ID: 20065257 [No Abstract] [Full Text] [Related]
14. Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer. Garant A; Des Groseilliers S; Martin L; Ferland É; Vuong T Clin Oncol (R Coll Radiol); 2011 Sep; 23(7):497-8. PubMed ID: 21576010 [No Abstract] [Full Text] [Related]
15. First description of an uterine perforation potentially imputable to treatment with bevacizumab. Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310 [No Abstract] [Full Text] [Related]
17. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369 [TBL] [Abstract][Full Text] [Related]
18. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme. Kilickap S; Oztoprak I; Yucel B Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408 [No Abstract] [Full Text] [Related]
19. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159 [TBL] [Abstract][Full Text] [Related]